AZRX:NSD-AzurRx BioPharma Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.75

Change

-0.09 (-2.34)%

Market Cap

USD 0.04B

Volume

0.95M

Avg Analyst Target

USD 3.17 (-15.56%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is based in Boca Raton, Florida.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-10.60 (-2.41%)

USD175.37B 51.33 42.01
BNTX BioNTech SE

-13.47 (-3.61%)

USD90.37B 20.44 14.68
REGN Regeneron Pharmaceuticals Inc

-1.30 (-0.20%)

USD69.86B 11.79 9.07
VRTX Vertex Pharmaceuticals Incorpo..

+1.20 (+0.64%)

USD48.54B 24.67 16.64
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

+17.90 (+4.65%)

USD35.84B N/A N/A
SGEN Seagen Inc

+2.64 (+1.72%)

USD27.94B 47.92 37.66
GMAB Genmab A/S

+0.84 (+1.99%)

USD27.66B 70.01 8.47
RPRX Royalty Pharma plc

+0.12 (+0.31%)

USD23.30B 31.08 12.35
ALNY Alnylam Pharmaceuticals Inc

+0.14 (+0.07%)

USD22.60B N/A N/A

ETFs Containing AZRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 286.60% 97% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 286.60% 97% A+ 98% A+
Trailing 12 Months  
Capital Gain 360.12% 96% A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 360.12% 96% A 97% A+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -24.10% 7% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.10% 7% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 38.44% 76% C 47% F
Risk Adjusted Return -62.68% 9% F 4% F
Market Capitalization 0.04B 5% F 7% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.23 35% F 28% F
Price / Cash Flow Ratio -3.20 26% F 60% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -1,271.87% 3% F 10% F
Return on Invested Capital -1,305,238,728.00% 0% N/A 0% N/A
Return on Assets -233.79% 1% F 0% N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.19 96% A 93% A
Short Percent 1.68% 84% B 65% D
Beta 1.51 42% F 28% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector